Outlook Therapeutics competitors

View the competitive landscape for Outlook Therapeutics, featuring companies like Kalaris Therapeutics, Novartis, and Roche. Mapping a different industry? Browse our competitor database or generate a competitor list for any company.

Company icon
Outlook Therapeutics

Late-stage biopharmaceutical company developing ophthalmic bevacizumab

outlooktherapeutics.com

List of Outlook Therapeutics competitors

  • Company icon

    Kalaris Therapeutics

    Clinical-stage biopharmaceutical company developing retinal disease treatments

    kalaristx.com
  • Company icon

    Novartis

    Pharmaceutical firm marketing various treatments for neovascular age-related macular degeneration

    novartis.com
  • Company icon

    Roche

    Global healthcare company providing innovative biologics for wet AMD treatment

    roche.com
  • Company icon

    Merck

    Biotechnology company advancing clinical programs for diabetic macular edema

    merck.com
  • Company icon

    Regeneron

    Biotechnology company manufacturing leading anti-VEGF therapies for retinal disorders

    regeneron.com
  • Company icon

    EyePoint Pharmaceuticals

    Company developing sustained-release therapeutics for serious retinal diseases

    eyepoint.bio
  • Company icon

    Ocular Therapeutix

    Biopharmaceutical company focused on hydrogel-based formulations for eye conditions

    ocutx.com
  • Company icon

    Opthea

    Biopharmaceutical company developing VEGF-C/D trap therapies for wet AMD

    opthea.com
  • Company icon

    Adverum Biotechnologies

    Clinical-stage gene therapy company targeting ocular and rare diseases

    adverum.com
  • Company icon

    Kodiak Sciences

    Clinical-stage company developing antibody biopolymer conjugates for retinal diseases

    kodiak.com
  • Company icon

    REGENXBIO

    Clinical-stage biotechnology company developing gene therapies for retinal conditions

    regenxbio.com
Track Outlook Therapeutics & Its Competitors

Follow their latest moves with a real-time news feed and summaries delivered straight to your inbox.